Document is current
Any future updates will be listed below
-
Authors
Bossowski, Jozef P. https://orcid.org/0000-0003-2101-2863
Pillai, Ray https://orcid.org/0000-0002-8335-3463
Kilian, John
Wong Lau, Angela https://orcid.org/0009-0000-4685-3314
Nakamura, Mari
Rashidfarrokhi, Ali
Hao, Yuan
Li, Ruxuan
Wu, Katherine https://orcid.org/0000-0002-0472-0166
Hattori, Takamitsu https://orcid.org/0000-0002-5502-2595
Glasser, Eliezra https://orcid.org/0000-0002-1371-4980
Koide, Akiko https://orcid.org/0000-0003-1796-7077
Wang, Lidong
Moreira, Andre L.
Hajdu, Cristina
Rajalingam, Sahith
LeBoeuf, Sarah E.
Le, Hortense
Lee, Seungeun https://orcid.org/0009-0007-6791-8296
Oh, Jin Woo https://orcid.org/0000-0002-3545-5481
Joe, Cheolyong
Kim, Hyemin
Ock, Chan-Young
Lee, Se-Hoon https://orcid.org/0000-0002-9219-3350
Wang, Hao
Patel, Angana A. H.
Sayin, Volkan I. https://orcid.org/0000-0002-5225-8260
Tsirigos, Aristotelis https://orcid.org/0000-0002-7512-8477
Wong, Kwok-Kin https://orcid.org/0000-0001-6323-235X
Koralov, Sergei B. https://orcid.org/0000-0002-4843-3791
Pende, Mario https://orcid.org/0000-0002-7864-8937
Sánchez-Rivera, Francisco J. https://orcid.org/0000-0002-8466-8563
Simeone, Diane M.
Zervantonakis, Ioannis K. https://orcid.org/0000-0003-2386-9553
Koide, Shohei https://orcid.org/0000-0001-5473-4358
Papagiannakopoulos, Thales https://orcid.org/0000-0002-2251-1624
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 15 January 2026
First Online: 18 February 2026
Competing interests
: T.P. received funding from Pfizer Medical Education Group, Dracen Pharmaceuticals, Kymera Therapeutics, Bristol Myers Squibb and Agios Pharmaceuticals, not related to the submitted work. S.K. is a co-founder of, receives consulting fees from and holds equity in Aethon Therapeutics; is a co-founder of and holds equity in Revalia Bio; and has received research funding from Aethon Therapeutics, Argenx BVBA, Black Diamond Therapeutics and Puretech Health, all outside of the current work. S.B.K. has previously received funding from Micreos, BMS and Kymera Therapeutics. T.P., S.K., J.P.B. and J.K. are listed as inventors on a patent application (PCT/US24/19489: ‘Anti-lipocalin-2 antibodies and uses thereof’).
